Drugs produced in U.S.-owned and operated pharmaceutical manufacturing plants in Puerto Rico are more likely to have quality problems than those produced by the same firm in a matched plant on the mainland, a study released Tuesday by Ohio State University's Fisher College of Business.
Merck & Co.’s reported plans to cut back its workforce by about 13,000 by 2015 will not affect its local operations, Frank Gutiérrez, general manager of Merck Puerto Rico and the Caribbean, said Friday.
Pharmaceutical companies doing business in Puerto Rico will not show any significant growth this year, pressured by upcoming patent expirations and underperforming economic conditions, Irish research firm Research and Markets said in its most recent industry report.
A Dow Jones/Factiva content provider since 2014
Subscribe to our Dollars & Sense podcast!
